Long-term safety with axitinib in previously treated patients with metastatic renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 13, Issue 6, 2015, Pages 540-547.e7

  Rini, Brian I ^a   Escudier, Bernard ^b   Hariharan, Subramanian ^c   Roberts, W Gregory ^c   Tarazi, Jamal ^c   Rosbrook, Brad ^c   Askerova, Zena ^d   Deannuntis, Liza L ^c   Motzer, Robert J ^e  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Pfizer Ltd   (United States)

^d PFIZER INC   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

adverse events; tyrosine kinase inhibitor; vascular endothelial growth factor receptor

Indexed keywords

AMYLASE; AXITINIB; CREATININE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; AGED; AMYLASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BACKACHE; COUGHING; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DRUG SAFETY; DYSPHONIA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SOLID TUMOR; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DRUG ADMINISTRATION; KIDNEY NEOPLASMS; METASTASIS; RETROSPECTIVE STUDY;

CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES;

EID: 84947866224     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2015.07.001     Document Type: Article

References (22)

1. D. Shek, B. Tomlinson, M. Brown, and et al. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients Clin Genitourin Cancer 10 2012 93 98
2. R.B. Cohen, and S. Oudard Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities Invest New Drugs 30 2012 2066 2079
3. T. Eisen, C.N. Sternberg, C. Robert, and et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies J Natl Cancer Inst 104 2012 93 113
4. D.D. Hu-Lowe, H.Y. Zou, M.L. Grazzini, and et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 2008 7272 7283
5. Inlyta (axitinib) tablets for oral administration [prescribing information] 2012 Pfizer Inc New York, NY
6. O. Rixe, R.M. Bukowski, M.D. Michaelson, and et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984
7. B.I. Rini, G. Wilding, G. Hudes, and et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
8. B.I. Rini, B. Escudier, P. Tomczak, and et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
9. Y. Tomita, H. Uemura, H. Fujimoto, and et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma Eur J Cancer 47 2011 2592 2602
10. S.K. Qin, F. Bi, J. Jin, and et al. Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study Onco Targets Ther 8 2015 1363 1373
11. B.I. Rini, B. Melichar, T. Ueda, and et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial Lancet Oncol 14 2013 1233 1242
12. T.E. Hutson, V. Lesovoy, S. Al-Shukri, and et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial Lancet Oncol 14 2013 1287 1294
13. H.S. Rugo, R.S. Herbst, G. Liu, and et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results J Clin Oncol 23 2005 5474 5483
14. Y. Fujiwara, N. Kiyota, N. Chayahara, and et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients Invest New Drugs 30 2012 1055 1064
15. J.H. Schiller, T. Larson, S.H. Ou, and et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study J Clin Oncol 27 2009 3836 3841
16. E.E. Cohen, L.S. Rosen, E.E. Vokes, and et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study J Clin Oncol 26 2008 4708 4713
17. J. Fruehauf, J. Lutzky, D. McDermott, and et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma Clin Cancer Res 17 2011 7462 7469
18. L.D. Locati, L. Licitra, L. Agate, and et al. Treatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments Cancer 120 2014 2694 2703
19. B.I. Rini, T. de La Motte Rouge, A.L. Harzstark, and et al. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib Clin Genitourin Cancer 11 2013 107 114
20. H. Izzedine, C. Massard, J.P. Spano, and et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management Eur J Cancer 46 2010 439 448
21. B.I. Rini, D.I. Quinn, M. Baum, and et al. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial Target Oncol 10 2015 45 53
22. Porta C, Gore ME, Rini BI, et al. Long-term safety of sunitinib in metastatic renal cell carcinoma. Eur Urol 2015 Jul 24. pii: S0302-2838(15)00610-7. http://dx.doi.org/10.1016/j.eururo.2015.07.006. [Epub ahead of print]